Ignite Creation Date:
2025-12-24 @ 11:49 PM
Ignite Modification Date:
2025-12-25 @ 9:43 PM
Study NCT ID:
NCT04519151
Status:
RECRUITING
Last Update Posted:
2023-06-08
First Post:
2020-08-04
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sponsor:
Sheba Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-04-12
Start Date Type:
ACTUAL
Primary Completion Date:
2023-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-11
Completion Date Type:
ESTIMATED
First Submit Date:
2020-08-04
First Submit QC Date:
None
Study First Post Date:
2020-08-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-06-06
Last Update Post Date:
2023-06-08
Last Update Post Date Type:
ACTUAL